Pregnenolone in the Management of Schizophrenia Patients
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Pregnenolone is a "neurosteroid" and possesses intrinsic behavioral and brain effects in
animals, affecting the GABA(A) and other receptors. Pregnenolone is serves as the precursor
for dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS). There is evidence of
efficacy of DHEA augmentation in schizophrenia, we therefore sought to examine the efficacy
of augmentation of antipsychotic treatment of schizophrenia patients with pregnenolone. It is
hypothesized that the combined effect of antipsychotic agents and pregnenolone would be
beneficial in the treatment of negative,depressive, and cognitive symptoms.
Phase:
Phase 1
Details
Lead Sponsor:
Sha'ar Menashe Mental Health Center Sha’ar Menashe Mental Health Center